

mammalian patients, wherein said method comprises mixing apoptotic bodies and/or apoptotic cells with a pharmaceutically acceptable excipient.

21. The method of claim 20 wherein apoptotic bodies and/or apoptotic cells are in a liquid suspension along with viable cells.

22. The method of claim 21, wherein the apoptotic bodies and/or apoptotic cells comprise from 10% to 90% of the cellular portion of the suspension.

*a
cont.*
23. The method of claim 22 wherein the apoptotic bodies and/or apoptotic cells comprise from 30% to 70% of the cellular portion of the suspension.

24. The method of claim 20 wherein the apoptotic bodies and/or cells are derived from extracorporeal treatment of blood cells compatible with those of the mammalian patient.

25. The method of claim 20, wherein the apoptotic bodies and/or cells are derived from established cultured cell lines.

26. The method of claim 24, wherein the blood cells are white blood cells of blood compatible with that of the mammalian patient.

27. The method of claim 26, wherein the blood cells are the patient's own white blood cells.

28. The method of claim 27, wherein the blood cells are the patient's own T lymphocytes.

29. The method of claim 20, wherein the disorder is selected from the group consisting of Alzheimer's disease, senile dementia, multiple sclerosis, depression, Down's syndrome, Huntington's disease, peripheral neuropathies, spinal cord disease, neuropathic joint disease, chronic inflammatory demyelinating disease (CIPD), neuropathies including mononeuropathy, polyneuropathy, symmetrical distal sensory neuropathy, cystic fibrosis, neuromuscular junction disorders, myasthenias and Parkinson's disease.

*a
cont.*

30. The method of claim 20, wherein a dosage of the pharmaceutical composition comprises from 10,000 to 10,000,000 apoptotic bodies and/or apoptotic cells per kilogram of body weight of said mammalian patient.

31. The method of claim 30, wherein the dosage contains from 500,000 to 5,000,000 apoptotic bodies and/or apoptotic cells per kilogram of body weight of said patient.

32. The method of claim 30, wherein the dosage contains from 1,500,000 to 4,000,000 apoptotic bodies and/or apoptotic cells per kilogram of body weight of the patient.

33. A method for treating and/or preventing neurodegenerative and other neurological medical disorders in a mammalian patient, said method comprising administering to said patient an effective amount of a pharmaceutical composition comprising apoptotic bodies and/or apoptotic cells.

*a 1
and*
34. The method of claim 33, wherein said apoptotic bodies and/or apoptotic cells are in a liquid suspension along with viable cells.

35. The method of claim 34, wherein the apoptotic bodies and/or apoptotic cells comprise 10% to 90% of the cellular portion of the suspension.

36. The method of claim 35, wherein the apoptotic bodies and/or apoptotic cells comprise from 30% to 70% of the cellular portion of the suspension.

37. The method of claim 33, wherein the apoptotic bodies and/or apoptotic cells are derived from extracorporeal treatment of blood cells compatible with those of the mammalian patient.

38. The method of claim 33, wherein the apoptotic bodies and/or apoptotic cells are derived from established cultured cell lines.

39. The method of claim 37, wherein the blood cells are white blood cells of blood compatible with that of the mammalian patient.

40. The method of claim 39, wherein the blood cells are the patient's own white blood cells.

41. The method of claim 40, wherein the blood cells are the patient's own T lymphocytes.

*at
unt*

42. The method of claim 33, wherein the disorder is selected from the group consisting of Alzheimer's disease, senile dementia, multiple sclerosis, depression, Down's syndrome, Huntington's disease, peripheral neuropathies, spinal cord disease, neuropathic joint disease, chronic inflammatory demyelinating disease (CIPD), neuropathies including mononeuropathy, polyneuropathy, symmetrical distal sensory neuropathy, cystic fibrosis, neuromuscular junction disorders, myasthenias and Parkinson's disease.

43. The method of claim 34, wherein a dosage of the pharmaceutical composition comprises from 10,000 to 10,000,000 apoptotic bodies and/or apoptotic cells per kilogram of body weight of said mammalian patient.

44. The method of claim 43, wherein the dosage contains from 500,000 to 5,000,000 apoptotic bodies and/or apoptotic cells per kilogram of body weight of said patient.

45. The method of claim 43, wherein the dosage contains from 1,500,000 to 4,000,000 apoptotic bodies and/or apoptotic cells per kilogram of body weight of the patient.

46. A method for the treatment and/or prevention of T-cell mediated and inflammatory disorders in a mammalian patient, wherein said method comprises administering to said mammalian patient an effective amount of a pharmaceutical composition comprising apoptotic bodies and/or apoptotic cells.--
